X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs ASTRAZENECA PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. ASTRAZENECA PHARMA WOCKHARDT LTD./
ASTRAZENECA PHARMA
 
P/E (TTM) x -9.2 137.7 - View Chart
P/BV x 2.2 20.9 10.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT LTD.   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
ASTRAZENECA PHARMA
Mar-14
WOCKHARDT LTD./
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0121,285 78.8%   
Low Rs532634 83.8%   
Sales per share (Unadj.) Rs355.9189.6 187.7%  
Earnings per share (Unadj.) Rs-60.3-0.2 29,605.8%  
Cash flow per share (Unadj.) Rs-46.83.8 -1,216.3%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.868.6 375.6%  
Shares outstanding (eoy) m110.6325.00 442.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.25.1 42.9%   
Avg P/E ratio x-12.8-4,712.7 0.3%  
P/CF ratio (eoy) x-16.5249.6 -6.6%  
Price / Book Value ratio x3.014.0 21.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,37923,988 355.9%   
No. of employees `0006.31.6 401.2%   
Total wages/salary Rs m9,3711,605 584.0%   
Avg. sales/employee Rs Th6,295.03,040.2 207.1%   
Avg. wages/employee Rs Th1,498.31,029.2 145.6%   
Avg. net profit/employee Rs Th-1,066.3-3.3 32,658.7%   
INCOME DATA
Net Sales Rs m39,3694,740 830.6%  
Other income Rs m1,20292 1,305.4%   
Total revenues Rs m40,5714,832 839.7%   
Gross profit Rs m18-130 -14.1%  
Depreciation Rs m1,495101 1,477.6%   
Interest Rs m2,5550-   
Profit before tax Rs m-2,830-139 2,037.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582139 -2,578.8%   
Tax Rs m2575 5,049.1%   
Profit after tax Rs m-6,669-5 131,011.8%  
Gross profit margin %0-2.7 -1.7%  
Effective tax rate %-9.1-3.7 247.9%   
Net profit margin %-16.9-0.1 15,772.8%  
BALANCE SHEET DATA
Current assets Rs m33,7962,726 1,239.6%   
Current liabilities Rs m26,9172,435 1,105.4%   
Net working cap to sales %17.56.1 284.2%  
Current ratio x1.31.1 112.1%  
Inventory Days Days7974 107.6%  
Debtors Days Days8941 218.9%  
Net fixed assets Rs m39,6641,035 3,831.2%   
Share capital Rs m55350 1,106.4%   
"Free" reserves Rs m27,968942 2,967.8%   
Net worth Rs m28,5221,716 1,662.1%   
Long term debt Rs m21,7310-   
Total assets Rs m81,6204,156 1,963.9%  
Interest coverage x-0.1NM-  
Debt to equity ratio x0.80-  
Sales to assets ratio x0.51.1 42.3%   
Return on assets %-5.0-0.1 4,115.1%  
Return on equity %-23.4-0.3 7,882.3%  
Return on capital %-7.70-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m9,807375 2,618.0%   
Fx outflow Rs m1,789470 380.4%   
Net fx Rs m8,019-96 -8,391.9%   
CASH FLOW
From Operations Rs m684-8 -8,449.4%  
From Investments Rs m6,302-146 -4,325.6%  
From Financial Activity Rs m-7,695862 -892.4%  
Net Cashflow Rs m-664709 -93.7%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.3 0.3 766.7%  
FIIs % 7.7 15.7 49.0%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   67,757 12,856 527.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare WOCKHARDT LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 222 Points Higher; Telecom and FMCG Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note today. Gains were largely seen in the telecom sector and FMCG sector.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (4QFY18); Net Profit Down 13.4%

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, WOCKHARDT LTD. has posted a net profit of Rs 2 bn (down 13.4% YoY). Sales on the other hand came in at Rs 10 bn (up 17.9% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1%

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Sintex's Auditor Resigns. How You Can Protect Yourself from Such Stocks(The 5 Minute Wrapup)

Jul 20, 2018

While the attack on the bad corporate governance is an overhang in the near term...this can be a game-changer in the years to come.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Jul 23, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS